Ensysce Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 13, 2023, regarding events occurring on January 12, 2023. Ensysce Biosciences, Inc. (Ensysce), a Delaware corporation, entered into a Letter Agreement amending its existing Securities Purchase Agreement (SPA) dated June 30, 2022. The Company is an emerging growth company with common stock trading on The Nasdaq Stock Market under the symbol ENSC.
Key Financial Metrics and Obligations
- Outstanding Debt: The remaining principal balance of the senior secured convertible promissory notes (Notes) was $3,339,931 as of January 12, 2023.
- Conversion Price Adjustment: The conversion price for the Notes was reduced from $2.006 to $0.7512 per share (New Conversion Price).
- Duration of Adjustment: The New Conversion Price applies from January 12, 2023, through May 12, 2023. The prior price of $2.006 will resume thereafter.
- Warrants: There are 466,788 outstanding warrants to purchase common stock (adjusted for a reverse stock split in October 2022). The exercise price of these warrants remains unchanged.
- Liquidity and Registration: The Company agreed to register additional shares of common stock required upon conversion of the Notes if they exceed shares already registered on a Form S-3 declared effective on December 29, 2022.
Material Changes Versus Prior Period
The primary material change is the amendment to the conversion terms of the outstanding Notes. Previously, the conversion price was $2.006 per share. The new agreement lowers this price to $0.7512 per share for a four-month period. This reduction significantly increases the number of shares that could be issued upon conversion of the remaining $3.34 million debt balance. Additionally, the agreement modifies the acceleration of payment provisions, allowing accelerations permitted under the Notes to be made over four conversion notices instead of two during the specified period.
Guidance, Outlook, and Risks
- Dilution Risk: The Letter Agreement may result in the issuance of more than 20% of the Company's outstanding common stock. The New Conversion Price was set to meet Nasdaq minimum price requirements to avoid the need for stockholder approval.
- Valuation Basis: The New Conversion Price of $0.7512 was determined as the lower of the Nasdaq Official Closing Price immediately preceding the signing ($0.7600) or the five-day average closing price ($0.7512).
- Cash True-Up Deferral: The Company and investors agreed that any cash true-up payments based on the New Conversion Price, triggered by interest payments or redemption notices, will not be required for 120 days.
- Conditions: The transaction is subject to certain conditions that the Company must satisfy.
Key Facts for Investor Verification
- Verify the exact number of shares issuable upon conversion of the $3,339,931 note balance at the new price of $0.7512 versus the old price of $2.006.
- Confirm the status of the Form S-3 registration and whether additional registration statements are required to cover the increased share issuance.
- Monitor the Company's cash position given the potential for accelerated payments and the deferral of cash true-up obligations.
- Review the specific conditions in the Letter Agreement that must be satisfied for the transaction to remain effective.
- Check for any subsequent filings regarding the expiration of the four-month period on May 12, 2023, and the reversion to the $2.006 conversion price.